President Ilham Aliyev on February 16 received credentials of the newly appointed Ambassador Extraordinary and Plenipotentiary of the Republic of Belarus Andrei Ravkov.
Trend:
President of the Republic of Azerbaijan Ilham Aliyev has received credentials of the newly appointed Ambassador Extraordinary and Plenipotentiary of the Republic of Belarus Andrei Ravkov.
MENAFN16022021000187011040ID1101607482 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
(MENAFN - CDN Newswire) Newly added by MarketsandResearch.biz study on Global Organic Fat-free Milk Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 contains a detailed analysis of data through industrial dynamics which has a major impact on the growth of the market. The report categorizes the global Organic Fat-free Milk market by segmented top key players, type, application, marketing channel, and regions. The report provides a complete understanding of the market in the coming years. The report tracks the latest market dynamics, such as driving factors, restraining factors, and industry news like mergers, acquisitions, and investments. The market research report provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts.
NOXXON Pharma N.V.: NOXXON Enrolls First Patient in the High Dose Cohort of Trial Combining NOX-A12 With Radiotherapy in Newly Diagnosed Brain Cancer
NOXXON Pharma N.V.
(Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the enrollment and first week of treatment of the first patient in the third, high dose cohort of the Phase 1/2 clinical trial. The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients who would not benefit clinically from treatment with standard chemotherapy.